GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BUE:AZN) » Definitions » Cyclically Adjusted Price-to-FCF

AstraZeneca (BUE:AZN) Cyclically Adjusted Price-to-FCF : 56.45 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is AstraZeneca Cyclically Adjusted Price-to-FCF?

As of today (2024-05-24), AstraZeneca's current share price is ARS214.50. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ARS3.80. AstraZeneca's Cyclically Adjusted Price-to-FCF for today is 56.45.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BUE:AZN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 12.25   Med: 25.15   Max: 73.79
Current: 65.78

During the past years, AstraZeneca's highest Cyclically Adjusted Price-to-FCF was 73.79. The lowest was 12.25. And the median was 25.15.

BUE:AZN's Cyclically Adjusted Price-to-FCF is ranked worse than
72.12% of 312 companies
in the Drug Manufacturers industry
Industry Median: 33.315 vs BUE:AZN: 65.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share data for the three months ended in Mar. 2024 was ARS475.796. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is ARS3.80 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Price-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.17 48.06 60.81 62.36 57.15

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.90 62.58 58.91 57.15 56.63

Competitive Comparison of AstraZeneca's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AstraZeneca's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=214.50/3.8
=56.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=475.796/131.6000*131.6000
=475.796

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 6.036 99.800 7.959
201409 10.224 100.000 13.455
201412 9.288 99.900 12.235
201503 -7.997 99.600 -10.566
201506 3.132 100.100 4.118
201509 9.001 100.200 11.822
201512 0.368 100.400 0.482
201603 10.240 100.400 13.422
201606 -9.062 101.000 -11.808
201609 5.243 101.500 6.798
201612 16.516 102.200 21.267
201703 -3.617 102.700 -4.635
201706 -1.055 103.500 -1.341
201709 26.140 104.300 32.982
201712 6.706 105.000 8.405
201803 -7.538 105.100 -9.439
201806 -5.787 105.900 -7.191
201809 5.809 106.600 7.171
201812 54.013 107.100 66.369
201903 -35.360 107.000 -43.489
201906 -3.269 107.900 -3.987
201909 32.481 108.400 39.433
201912 45.069 108.500 54.664
202003 -11.204 108.600 -13.577
202006 3.285 108.800 3.973
202009 63.206 109.200 76.171
202012 77.475 109.400 93.197
202103 100.051 109.700 120.025
202106 38.740 111.400 45.765
202109 69.217 112.400 81.041
202112 45.258 114.700 51.926
202203 197.342 116.500 222.920
202206 54.380 120.500 59.389
202209 162.123 122.300 174.451
202212 198.171 125.300 208.135
202303 210.593 126.800 218.565
202306 190.000 129.400 193.230
202309 501.371 130.100 507.152
202312 330.149 130.500 332.932
202403 475.796 131.600 475.796

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (BUE:AZN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AstraZeneca Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (BUE:AZN) Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (BUE:AZN) Headlines

From GuruFocus

AstraZeneca: Growth Is Still a Better Choice

By Nathan Aisenstadt 11-15-2023